<?xml version='1.0' encoding='utf-8'?>
<document id="20698928"><sentence text="Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide."><entity charOffset="116-144" id="DDI-PubMed.20698928.s1.e0" text="sulphonylureas glibenclamide" /><entity charOffset="146-157" id="DDI-PubMed.20698928.s1.e1" text="glimepiride" /><entity charOffset="161-170" id="DDI-PubMed.20698928.s1.e2" text="glipizide" /><pair ddi="false" e1="DDI-PubMed.20698928.s1.e0" e2="DDI-PubMed.20698928.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20698928.s1.e0" e2="DDI-PubMed.20698928.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20698928.s1.e0" e2="DDI-PubMed.20698928.s1.e2" /><pair ddi="false" e1="DDI-PubMed.20698928.s1.e1" e2="DDI-PubMed.20698928.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20698928.s1.e1" e2="DDI-PubMed.20698928.s1.e2" /></sentence><sentence text="Sulphonylureas are widely used in the treatment of type 2 diabetes mellitus (T2DM)"><entity charOffset="0-14" id="DDI-PubMed.20698928.s2.e0" text="Sulphonylureas" /></sentence><sentence text=" Based on laboratory findings, we determined the clinical significance of potential CYP2C9-mediated drug-drug interactions in hospitalized patients receiving glibenclamide, glimepiride or glipizide, all of which are metabolized by CYP2C9, together with a CYP2C9 inhibitor"><entity charOffset="158-171" id="DDI-PubMed.20698928.s3.e0" text="glibenclamide" /><entity charOffset="173-184" id="DDI-PubMed.20698928.s3.e1" text="glimepiride" /><entity charOffset="188-197" id="DDI-PubMed.20698928.s3.e2" text="glipizide" /><pair ddi="false" e1="DDI-PubMed.20698928.s3.e0" e2="DDI-PubMed.20698928.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20698928.s3.e0" e2="DDI-PubMed.20698928.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20698928.s3.e0" e2="DDI-PubMed.20698928.s3.e2" /><pair ddi="false" e1="DDI-PubMed.20698928.s3.e1" e2="DDI-PubMed.20698928.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20698928.s3.e1" e2="DDI-PubMed.20698928.s3.e2" /></sentence><sentence text="" /><sentence text="An observational pharmaco-epidemiological database study was performed in a university hospital setting with 3884 patients with T2DM" /><sentence text="" /><sentence text="Efficacy and safety of sulphonylurea therapy during the potential interaction (sulphonylurea treatment with a CYP2C9 inhibitor) vs"><entity charOffset="23-36" id="DDI-PubMed.20698928.s7.e0" text="sulphonylurea" /><entity charOffset="79-92" id="DDI-PubMed.20698928.s7.e1" text="sulphonylurea" /><pair ddi="false" e1="DDI-PubMed.20698928.s7.e0" e2="DDI-PubMed.20698928.s7.e0" /><pair ddi="false" e1="DDI-PubMed.20698928.s7.e0" e2="DDI-PubMed.20698928.s7.e1" /></sentence><sentence text=" control periods (sulphonylurea treatment without a CYP2C9 inhibitor) were estimated using laboratory parameters"><entity charOffset="18-31" id="DDI-PubMed.20698928.s8.e0" text="sulphonylurea" /></sentence><sentence text="" /><sentence text="Almost 20% of patients were exposed to a potential drug-drug interaction with a CYP2C9 inhibitor during sulphonylurea treatment"><entity charOffset="104-117" id="DDI-PubMed.20698928.s10.e0" text="sulphonylurea" /></sentence><sentence text=" More than 75% of the potential interactions occurred with trimethoprim, metronidazole and fluconazole"><entity charOffset="59-71" id="DDI-PubMed.20698928.s11.e0" text="trimethoprim" /><entity charOffset="73-86" id="DDI-PubMed.20698928.s11.e1" text="metronidazole" /><entity charOffset="91-102" id="DDI-PubMed.20698928.s11.e2" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.20698928.s11.e0" e2="DDI-PubMed.20698928.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20698928.s11.e0" e2="DDI-PubMed.20698928.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20698928.s11.e0" e2="DDI-PubMed.20698928.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20698928.s11.e1" e2="DDI-PubMed.20698928.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20698928.s11.e1" e2="DDI-PubMed.20698928.s11.e2" /></sentence><sentence text=" When all sulphonylureas were pooled and adjusted for age, gender, ward and sulphonylurea dose, mean and maximum fasting plasma glucose concentrations as well as maximum values of glycosylated haemoglobin were significantly lower during the interaction periods compared with control periods, whereas mean and minimum activities of alanine amino transferase and gamma-glutamyl transferase were higher"><entity charOffset="10-24" id="DDI-PubMed.20698928.s12.e0" text="sulphonylureas" /><entity charOffset="76-89" id="DDI-PubMed.20698928.s12.e1" text="sulphonylurea" /><entity charOffset="128-135" id="DDI-PubMed.20698928.s12.e2" text="glucose" /><pair ddi="false" e1="DDI-PubMed.20698928.s12.e0" e2="DDI-PubMed.20698928.s12.e0" /><pair ddi="false" e1="DDI-PubMed.20698928.s12.e0" e2="DDI-PubMed.20698928.s12.e1" /><pair ddi="false" e1="DDI-PubMed.20698928.s12.e0" e2="DDI-PubMed.20698928.s12.e2" /><pair ddi="false" e1="DDI-PubMed.20698928.s12.e1" e2="DDI-PubMed.20698928.s12.e1" /><pair ddi="false" e1="DDI-PubMed.20698928.s12.e1" e2="DDI-PubMed.20698928.s12.e2" /></sentence><sentence text=" The minimum fasting plasma glucose values were more often below the target range in patients with potential interactions"><entity charOffset="28-35" id="DDI-PubMed.20698928.s13.e0" text="glucose" /></sentence><sentence text=" The sulphonylurea dose did not differ significantly between patients who were or were not concomitantly treated with a potentially interacting drug"><entity charOffset="5-18" id="DDI-PubMed.20698928.s14.e0" text="sulphonylurea" /></sentence><sentence text="" /><sentence text="Concomitant use of a CYP2C9 inhibitor results in exaggerated pharmacodynamic effects of sulphonylureas and increases the risk of hypoglycaemia in T2DM patients receiving glibenclamide, glimepiride or glipizide"><entity charOffset="88-102" id="DDI-PubMed.20698928.s16.e0" text="sulphonylureas" /><entity charOffset="170-183" id="DDI-PubMed.20698928.s16.e1" text="glibenclamide" /><entity charOffset="185-196" id="DDI-PubMed.20698928.s16.e2" text="glimepiride" /><entity charOffset="200-209" id="DDI-PubMed.20698928.s16.e3" text="glipizide" /><pair ddi="false" e1="DDI-PubMed.20698928.s16.e0" e2="DDI-PubMed.20698928.s16.e0" /><pair ddi="false" e1="DDI-PubMed.20698928.s16.e0" e2="DDI-PubMed.20698928.s16.e1" /><pair ddi="false" e1="DDI-PubMed.20698928.s16.e0" e2="DDI-PubMed.20698928.s16.e2" /><pair ddi="false" e1="DDI-PubMed.20698928.s16.e0" e2="DDI-PubMed.20698928.s16.e3" /><pair ddi="false" e1="DDI-PubMed.20698928.s16.e1" e2="DDI-PubMed.20698928.s16.e1" /><pair ddi="false" e1="DDI-PubMed.20698928.s16.e1" e2="DDI-PubMed.20698928.s16.e2" /><pair ddi="false" e1="DDI-PubMed.20698928.s16.e1" e2="DDI-PubMed.20698928.s16.e3" /><pair ddi="false" e1="DDI-PubMed.20698928.s16.e2" e2="DDI-PubMed.20698928.s16.e2" /><pair ddi="false" e1="DDI-PubMed.20698928.s16.e2" e2="DDI-PubMed.20698928.s16.e3" /></sentence><sentence text="" /></document>